oXiris®膜连续性肾脏替代治疗在严重 EBV 介导的噬血细胞性淋巴组织细胞增生症中的应用：病例报告。
Continuous Renal Replacement Therapy with oXiris® Membrane in Severe Ebstein-Barr Virus-Mediated Hemophagocytic Lymphohistiocytosis: A Case Report.
机构信息
Department of Medicine, Hôpital du Sacré-Cœur de Montréal, Université de Montréal, Montreal, Québec, Canada.
Department of Medicine, Hôpital du Sacré-Cœur de Montréal, Université de Montréal, Montreal, Québec, Canada,
出版信息
Blood Purif. 2021;50(4-5):578-581. doi: 10.1159/000511724. Epub 2020 Dec 17.
Hemophagocytic lymphohistiocytosis (HLH), a life-threatening disease with uncontrolled immune activation and inflammatory reaction, often leads to a deadly cytokine storm. In severe Ebstein-Barr virus-triggered HLH receiving standard immunosuppression, continuous renal replacement therapy (CRRT) with oXiris® blood purification membrane resulted in a timely reduction of inflammatory markers and discontinuation of vasopressors. To our knowledge, this is the first report of successful use of the oXiris® membrane in HLH.
噬血细胞性淋巴组织细胞增生症（HLH）是一种危及生命的疾病，其特征为免疫激活和炎症反应失控，常导致致命的细胞因子风暴。在接受标准免疫抑制治疗的严重 EBV 触发的 HLH 患者中，使用 oXiris®血液净化膜进行持续肾脏替代治疗（CRRT）可及时降低炎症标志物并停用升压药。据我们所知，这是首例成功使用 oXiris®膜治疗 HLH 的报告。
Zotero 插件